Comparison of the effect of triamcinolone and dexmedetomidine injections in the treatment of heel pain

Comparison of the efficacy of triamcinolone and dexmedetomidine injection in the treatment of pain caused by plantar fasciitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170423033615N2

Enrollment

Registered

2022-12-02

Start date

2022-11-30

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heel pain and plantar fasciitis. Plantar fascial fibromatosis

Interventions

Intervention 1: Intervention group: Injection of 1 microgram per kilogram of dexmedetomidine plus 2 ml lidocaine 2% under ultrasound guidance with a 22-gauge needle, after prepping the injection site

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age 18 and above Patients with initial complaint of heel pain after weight bearing after a period of rest Heel pain and plantar fasciitis for more than three months Patients with unilateral chronic plantar fasciitis Failure to respond to conservative treatments Pain that goes away after a few minutes of walking but returns after prolonged walking or standing Pain caused by palpation of medial calcaneal tuberosity, dorsiflexion of the foot passively Chronic heel pain of three months or more without evidence of acute trauma to the heel VAS > 5 after taking the first step following rest Patients with satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Mechanical pains in the posterior part of the heel in the form of Achilles tendonitis/bursitis Neurological heel pain caused by nerve rupture Heel arthritis pain Traumatic heel pain Bilateral plantar fasciitis Heel pain for more than three months Skin ulcer around the heel and treatment of that area Sciatica pain; benign and malignant tumors; acute infection; diabetes; sensory neuropathy; peripheral vascular disease / autoimmune disease; fibromyalgia; chronic fatigue syndrome Light sensitivity disorder Pregnancy and breastfeeding

Design outcomes

Primary

Measure	Time frame
Pain level. Timepoint: Before starting treatment, 4 and 12 weeks after injection. Method of measurement: Visual analog scale (VAS) (0 None; 1-3 Mild; 4-7 Moderate; 8-10 Severe).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahshid Ghasemi MD

Shahid Beheshti University of Medical Sciences

mahshidghasemi@sbmu.ac.ir+98 21 2200 2763

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026